Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. - Peters S; Paz-Ares LG; Reck M; Carbone DP; Brahmer JR; Borghaei H; Lu S; O'Byrne KJ; John T; Ciuleanu TE; Schenker M; Bernabe Caro R; et al. (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025)